This suggests that MEG3 upregulation may be a downstream transcriptional or epigenetic response to chemotherapeutic stress, potentially involving activation of tumor suppressive signaling pathways such as p53 or PTEN (Xu et al., 2022; Assal et al., 2025). This evidence concerns the gene MEG3 and neoplasm.